Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. The company develops various product candidates based on its IMDZVex and GLAAS product discovery platforms. Its oncology clinical-stage product candidates include LV305, G305, and CMB305, which are in Phase-I clinical trials for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma. The company’s oncology clinical-stage product candidates also comprise G100 that is in Phase-I clinical trials for the treatment of patients with merkel cell carcinoma and sarcoma; and in pre-clinical stage f...
1616 Eastlake Avenue East
Seattle, WA 98102
Founded in 2008
Immune Design Corp. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 11:20 AM
Sep 25 15
Immune Design Corp. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 11:20 AM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Carlos V. Paya, Chief Executive Officer, President and Director.
Immune Design Corp. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Cash Flow Results Guidance for the Year Ending December 31, 2015
Aug 12 15
Immune Design Corp. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $1,780,000 against $1,938,000 a year ago. Loss from operations was $10,525,000 against $4,687,000 a year ago. Net loss attributable to common stockholders was $10,517,000 or $0.54 per basic and diluted share against $6,126,000 or $16.57 per basic and diluted share a year ago.
For the six months, the company reported total revenues of $3,718,000 against $1,089,000 a year ago. Loss from operations was $19,931,000 against $10,200,000 a year ago. Net loss attributable to common stockholders was $19,923,000 or $1.10 per basic and diluted share against $14,349,000 or $38.81 per basic and diluted share a year ago.
The company estimated net cash used in operating activities of $36.0 to $40.0 million for the year ending December 31, 2015. This is an increase from beginning of the year guidance, which was an estimated range of $33.0 to $37.0 for net cash used in operating activities.
Immune Design and Genentech Announce Phase 2 Cancer Immunotherapy Trial Collaboration
Aug 12 15
Immune Design announced it has entered into clinical trial collaboration with Genentech to evaluate the safety and efficacy of Immune Design's CMB305 cancer immunotherapy product candidate combined with the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) in a randomized Phase 2 trial in patients with soft tissue sarcoma. CMB305 is a 'prime-boost' cancer immunotherapy product designed to synergistically induce anti-tumor cytotoxic T lymphocytes (CTLs) to target NY-ESO-1, a tumor antigen found in a broad set of tumors. Atezolizumab is a PD-L1 antagonist and is designed to block inhibitory T-cell checkpoints and allow cytotoxic T cells to reach the tumor. The randomized, open label Phase 2 trial will evaluate CMB305 and atezolizumab in patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid/round-cell liposarcoma, two types of sarcoma that tend to express NY-ESO-1 broadly.